TetraLogic postpones IPO

By
A A A

TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, postponed its IPO on Thursday citing poor market conditions. The Malvern, PA-based company was founded in 2001. TetraLogic Pharmaceuticals initially filed confidentially on 9/16/2013. Oppenheimer & Co., Guggenheim Securities and Needham & Co. were set to be the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: TLOG

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

111,864,163
  • $3.91 ▲ 2.36%
76,404,746
  • $7.37 ▼ 5.03%
66,680,057
  • $15.25 ▼ 2.12%
61,293,760
  • $30.55 ▼ 6.09%
56,394,825
    $23 unch
55,005,642
  • $95.60 ▼ 2.60%
47,372,853
  • $95.02 ▼ 2.02%
44,783,481
  • $45.19 ▼ 2.40%
As of 7/31/2014, 04:07 PM